Research Analysts Set Expectations for VERA FY2025 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA) – Equities researchers at HC Wainwright issued their FY2025 EPS estimates for shares of Vera Therapeutics in a research report issued to clients and investors on Wednesday, March 5th. HC Wainwright analyst E. Arce anticipates that the company will post earnings of ($2.40) per share for the year. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics’ FY2026 earnings at ($1.79) EPS.

A number of other brokerages also recently issued reports on VERA. Guggenheim lifted their price objective on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Wolfe Research started coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price objective on the stock. JPMorgan Chase & Co. dropped their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research report on Tuesday. Wedbush boosted their target price on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Finally, The Goldman Sachs Group started coverage on shares of Vera Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $58.00 target price on the stock. One analyst has rated the stock with a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $64.67.

Vera Therapeutics Stock Down 2.2 %

Shares of Vera Therapeutics stock opened at $29.30 on Friday. The firm’s 50 day moving average price is $34.70 and its 200-day moving average price is $40.07. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics has a 52-week low of $25.99 and a 52-week high of $51.61. The company has a market cap of $1.86 billion, a P/E ratio of -11.23 and a beta of 1.17.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11.

Institutional Trading of Vera Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Huntington National Bank acquired a new stake in Vera Therapeutics during the 4th quarter valued at approximately $26,000. AlphaQuest LLC acquired a new stake in Vera Therapeutics during the 4th quarter valued at approximately $34,000. GF Fund Management CO. LTD. acquired a new stake in Vera Therapeutics during the 4th quarter valued at approximately $56,000. KBC Group NV lifted its stake in Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock valued at $105,000 after acquiring an additional 1,387 shares during the period. Finally, Summit Investment Advisors Inc. lifted its stake in shares of Vera Therapeutics by 16.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company’s stock valued at $196,000 after purchasing an additional 639 shares during the period. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $43.07, for a total transaction of $753,725.00. Following the completion of the sale, the chief executive officer now directly owns 85,942 shares in the company, valued at approximately $3,701,521.94. The trade was a 16.92 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders sold 52,500 shares of company stock worth $2,305,625. Company insiders own 21.70% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.